Clinical Study on Efficacy and Adverse Reactions of Tumor-targeted Drugs

Mingyuan Yang

doi:10.47297/taposatWSP2633-456927.20220302

PDF
Export
Share
Collection
Album

Clinical Study on Efficacy and Adverse Reactions of Tumor-targeted Drugs

Volume 3, Issue 2

Views: 0 Downloads: 3

Clinical Study on Efficacy and Adverse Reactions of Tumor-targeted Drugs
Clinical Study on Efficacy and Adverse Reactions of Tumor-targeted Drugs
Department of agriculture science ,Oregon state University, America,97333
Vol. 3, Issue 2, Pages: 82-88(2022)
Published： 2022 ，
DOI：10.47297/taposatWSP2633-456927.20220302
Accepted：

Scan QR Code

MINGYUAN YANG. (2022). Clinical Study on Efficacy and Adverse Reactions of Tumor-targeted Drugs. Theory and Practice of Science and Technology, 3(2), 82-88..
DOI：

MINGYUAN YANG. (2022). Clinical Study on Efficacy and Adverse Reactions of Tumor-targeted Drugs. Theory and Practice of Science and Technology, 3(2), 82-88.. DOI： 10.47297/taposatWSP2633-456927.20220302.

摘要

Abstract

With the further discovery and development of anti-tumor molecular biology and anti-specific tumor cell biology

the targeting research of anti-specific tumor drugs has shifted from traditional cytotoxic drugs to specific targeted anti-tumor drugs. According to the research and clinical use of specific targeted antitumor drugs in recent years

this paper will conduct in-depth research and understanding from the basic categories of common targeted antitumor drugs

new targeted antitumor drugs

possible rejection and development path. This paper aims to provide a possible direction for the better development and application of targeted specific antitumor drugs.

关键词

Keywords

Targeted antitumor drugsMolecular targeted therapyProtein tyrosine kinaseEpidermal growth factor receptor tumor family

references

Huiqiong Yang.Establishment and application of MGMT - DNA crosslink detection method (the Third Military Medical University).[2] Yandi Tan, Ju Huang, Xinyi Tang, Rui Li.(2021). Application of Drug Targeted Delivery Strategy in Tumor Immunotherapy. Chemistry of life, 41(12).[3] Abdel-Aziz, Kamal, A. , Mantawy, Eman, M. , Said, & Soliman, R. , et al. (2016). The ty-rosine kinase inhibitor, sunitinib malate, induces cognitive impairment in vivo via dysregu-lating vegfr signaling, apoptotic and autophagic machineries. Experimental Neurology.[4] Guodong Zhu, Yaofu Zhu, Zheng Zhang, Jiwei Huang, Xinan Sheng, Hao Zeng (2020). Consensus on the safety of acitinib, a molecular targeted drug for renal cell carcinoma Jour-nal of Modern Urology, V.25 (11), 16-21[5] Yahui Huang. Discovery and optimization of multi-target antitumor and antifungal lead compounds (Naval Medical University of the Chinese people’s Liberation Army).[6] Llovet, J. M. , Ricci, S. , Mazzaferro, V. , Hilgard, P. , & Vlierberghe, H. V. . (2008). Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine, 359(4).[7] Lingxiao Wang, Dian Xiao, & Xinbo Zhou (2015). Oral multi - target tyrosine kinase inhib-itor lovatinib Journal of clinical drug therapy, 05 (5), 11-14.[8] ChongweiWen, Degang Ning, Ruijiang Liu, Yewang Zhang (2012). Endocrine gland de-rived vascular endothelial growth factor, a new target of tumor starvation therapy Advances in biochemistry and Biophysics, 39 (7), 9.[9] Friedman, H. S. , MD Prados, Wen, P. Y. , Mikkelsen, T. , Schiff, D. , & Abrey, L. E. , et al. (2009). Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Journal of Clinical Oncology, 27(28), 4733-4740.[10]Zhenhe Zheng, Shaoen Li, & Weijun Luo (2013). Efficacy of cetuximab combined with concurrent cisplatin chemotherapy and intensity modulated radiotherapy in the treatment of locally advanced nasopharyngeal carcinoma Chinese and foreign medical, 32 (34), 2.[11]Attoub, S. , Arafat, K. , An Ge′ laude, Sultan, M. A. A. , & Bracke, M. . (2013). Frondoside a suppressive effects on lung cancer survival, tumor growth, angiogenesis, invasion, and metastasis. PLoS ONE, 8(1), e53087.[12]Liping Zhang (2020). Clinical study of selective targeted chemotherapy drug capecitabine in the treatment of breast cancer. Psychological monthly (8), 2.[13] Feng Xu (2005). Study on drug metabolizing enzymes in tumor tissues Drug evaluation (4).[14]Y Kojima, R Yoshie, H Kawamoto, A Shimo, T Uejima, & T Iwatani. (2019). Trastuzumab emtansine (t-dm1) plus s-1 in patients with trastuzumab-pretreated her2-positive advanced or metastatic breast cancer: a phase ib study. Oncology, 1-9.[15]Qianqian Xu, Changjun Wang, & Qiang Sun (2017). Three molecular typing and individualized targeting therapy of negative breast cancer. Chinese Journal of cancer prevention and treatment, 24 (11), 7.[16]Chun Liu, Yuting Liao, shunhuan Lin, Yun Jia, Ling Guan, & Ruinian Zheng, etc (2019). Effects of long chain non encoding rna-lncrna nucleolar RNA host gene 14 on proliferation and migration of breast cancer cells. Journal of practical medicine, 35 (19), 6.[17]Zhihua Sun, Hui Bing, Yiqiao Liu, Jiang Qian, & Sulan Luo (2017). Progress in targeted therapy of breast cancer. Life science research, 21 (3), 8.[18]Shaoyan Lin, Fei Ma, & binghe Xu (2018). Research progress of Pd-1/pd-l1 inhibitors in the treatment of three negative breast cancer. Journal of clinical drug therapy, 16 (7), 4.[19]Linjuan Wang, Chunyan Wu, & Ping Zhang (2012). Clinical observation of cetuximab combined with advanced colorectal cancer Journal of Beihua University: Natural Science Edition (5), 4.[20]Hongming Liu, Mingchen Wang(2006). A case of mental disorder after gefitinib withdrawal Journal of Clinical Oncology, 11 (11), 1.[21]Yu Taoran (2019). Artemisinin is expected to become a new drug for lowering blood lipid and anti-tumor Win the future: modern leadership.[22]X Li. (2017). Dihydroartemisinin selectively inhibits pdgfrα-positive ovarian cancer growth and metastasis through inducing degradation of pdgfrα protein. Cell Discov, 3, 17042.

Alert me when the article has been cited

Submit

No data

Related Author

No data

Related Institution

No data

⁰